US tariffs putting 100,000 jobs at risk in Switzerland

Economiesuisse warns that new US tariffs of 39% on Swiss imports, effective August 7, directly jeopardize 100,000 jobs, predominantly in the watchmaking, machinery, metals, and food sectors. While pharmaceutical products are currently exempt, the critical sector faces a contingent threat of tariffs up to 250% if drug prices are not reduced, potentially impacting an additional 13,900 jobs. This action, cited by the US as a measure to address the trade deficit, risks broader negative consequences for Swiss exporters and their supply chains, prompting calls for domestic regulatory relief to offset the competitive disadvantage.

Analysis

The imposition of a 39% US tariff on Swiss imports represents a material shock to the Swiss export economy, with business federation economiesuisse estimating an immediate risk to 100,000 jobs. The impact is concentrated in the watchmaking, machinery, metals, and food industries, which now face a significant competitive disadvantage in the US market. The analysis indicates the negative effects will likely extend beyond direct exporters to their domestic supply chains, amplifying the economic drag. Critically, while the vital pharmaceutical sector is currently exempt, it faces a severe contingent risk from a threatened 250% tariff linked to drug pricing negotiations, placing a significant overhang on a cornerstone of the Swiss economy. This dual pressure from implemented and threatened tariffs has prompted calls for domestic regulatory relief to improve framework conditions, alongside ongoing diplomatic efforts by the Swiss government to de-escalate the trade dispute.

Key Decisions for Investors

• Investors should immediately review and potentially reduce exposure to Swiss companies heavily reliant on US exports within the watchmaking, machinery, metals, and food sectors, as the 39% tariff will directly compress margins and erode competitiveness.
• While the Swiss pharmaceutical sector is currently spared, the contingent threat of a 250% tariff introduces significant uncertainty, warranting a cautious stance or hedging strategies for positions in this industry until there is more clarity on US drug price negotiations.
• Monitor Swiss domestic policy for potential regulatory relief measures, as any government action to lighten the burden on companies could partially mitigate the negative impact of the tariffs and create selective opportunities.